Fewer than a tenth of people who could benefit from weight-loss injections such as Wegovy can access them, warns the World Health Organization as it releases its first recommendations on the therapies.
With more than one billion people worldwide now classified as obese, it is advocating for broader and more equitable access to this class of drugs.
Based on forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"The latest guidelines recognises that obesity is a lifelong illness that can be addressed with thorough and lifelong care," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are major hurdles to universal access to the jabs that can assist patients in reducing substantial weight, explains the agency.
GLP-1 Therapy Scarcity
Despite the current best projected case, the manufacturing of such drugs would only suffice for around 100 million people – less than 10% of those who need them, according to the health organization.
The advice urges countries and companies to widen availability, by measures such as patent sharing.
The intellectual property rights on the active ingredient – the core component of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Injections Function
The injections mimick a body's own hormone to delay gastric emptying, suppress the appetite and increase feelings of fullness so individuals consume fewer calories.
People usually start to lose weight after several weeks of commencing the once-weekly jabs.
Research indicates patients may put most of the weight back on a year later of halting the medication, when their typical appetite resume.
To be above a healthy weight raises your likelihood for experiencing diseases, like diabetes, heart disease, stroke, and specific malignancies.
Obesity impacts people in all nations and was responsible for 3.7 million fatalities worldwide in 2024, as per the health agency.
